Objective: To investigate the efficacy and safety of Tongxinluo capsule combined with low-molecular-weight heparin in the treatment of acute coronary syndrome

to provide evidence for clinical application of the remedy. Method: One hundred and twenty-two patients suffered from acute coronary syndrome were divided into two groups randomly

the control and the treatment group. The control group was given the low-molecular-weight heparin with the basic therapy

and the treatment group was given the Tongxinluo capsule on the basis of the control intervention. The treatment duration was both 4 weeks

the cardiac function

electrocardiogram curative effect

total effect and adverse effect were compared. Result: The left ventricular ejection fraction(LVEF)

cardiac output(co) and the ratio of E peak(E/A) over A peak in treatment group were significantly improved compared with those in the controls(P<0.05). The total effect in electrocardiogram curative was 63.9% in treatment group and 57.4% in the control group

the difference was not statistically significant. Anginal attacks and duration in treatment group were obviously less than those in the controls. Total clinical effect was 95.1% in the treatment group and 73.8% in the controls (P<0.05). The incidence of cardiovascular events is 6.6% in treatment group and 39.5% in control

The adverse effect was significant lower in treatment group (P<0.05). Conclusion: Tongxinluo capsule combined with western medicine is effect for the treatment of acute coronary syndrome. The treatment shows obviously improved cardiac function and angina symptoms

with higher clinical efficient and less adverse cardiovascular events. So

it is worth clinical application.